{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108426","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.568460+00:00","generated_at":"2026-05-17T13:30:31.712939+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexeo reports Q2 net loss $26.1M, advances LX2006 with Breakthrough Therapy, appoints new CFO","bullets":["Net loss $26.1M ($0.60/sh) vs $21.2M ($0.64/sh) in Q2 2024; cash $152.5M expected to fund operations into 2028.","LX2006 granted FDA Breakthrough Therapy designation based on interim data; registrational study expected early 2026.","Eight participants dosed in Phase I/II HEROIC-PKP2 trial of LX2020; interim data update expected H2 2025.","Closed $80M equity financing in May 2025; strategic partnership for non-viral RNA cardiac therapies.","Louis Tamayo appointed CFO effective Aug 15, 2025, succeeding Kyle Rasbach."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108426","json":"https://secwatch.observer/filing/0000950170-25-108426.json","markdown":"https://secwatch.observer/filing/0000950170-25-108426.md","text":"https://secwatch.observer/filing/0000950170-25-108426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/0000950170-25-108426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/lxeo-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:30:31.712939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}